cas 24666-56-6|| where to buy 3-Aminopiperidine-2,6-dione Hydrochloride

Produktname:3-Aminopiperidine-2,6-dione Hydrochloride

IUPAC Name:3-aminopiperidine-2,6-dione hydrochloride

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM119077-100g	in stock	Ȑȯ
CM119077-500g	in stock	ƃƃƥ
CM119077-1000g	in stock	ƿƿƿ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 24666-56-6 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:24666-56-6; Molekulare Formel:C5H9ClN2O2; Schmelzpunkt:-; SMILES-Code:O=C(C(N)CC1)NC1=O.[H]Cl; Dichte:

: Katalognummer:CM119077; Molekulargewicht:164.59; Siedepunkt:; Mdl-Nr.:MFCD11042437; Lagerung:Keep in inert atmosphere, store at room temperature.

: Piperidines; Piperidine is an azacycloalkane that is cyclohexane in which one of the carbons is replaced by a nitrogen. Although piperidine is a common organic compound, it is an immensely important class of compounds medicinally: the piperidine ring is the most common heterocyclic subunit among FDA approved drugs.; Piperidine,Piperidine Price; if you want to know the latest news about piperidine and piperidine price, please come to our website and get a quote for free.

: NX-2127; Existing BTK inhibitors directly bind to the active site of BTK and face challenges such as acquired resistance or incomplete responses over time. PROTAC-induced BTK degradation works as a novel alternative therapy for drug-resistant cancers. The latest journal Science publishes the identification of BTK mutations that are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Nurix Therapeutics’ TPD compound NX-2127 is a first-in-class, dual-function small-molecule protein degrader. It drives targeted BTK and transcription factor IKAROS (IKZF1/3) degradation through ubiquitination and proteasomal degradation, adding combined benefit. NX-2127 is under development of phase I clinical trials that shows promising results and a manageable safety profile for the treatment of relapsed/ refractory B-cell malignancies.

: MRT-2359; Aberrant MYC pathway activation is found in cancer cells, while MYC-induced protein translation depends on GSPT1. Molecular glues targeting GSPT1 is identified as a potential treatment method in oncology. Monte Rosa’s MRT-2359 is an oral and selective molecular glue degrader of the translation termination factor GSPT1. The targeted GSPT1 degradation results in disrupting MYC-driven protein translation and reducing MYC-oncogenic signaling.
MRT-2359 is in an ongoing phase 1/2 study in MYC-driven solid tumors with a current assessment of 0.75 mg dose level. The final phase 2 dose determination and updated clinical results are anticipated in the second half of 2024. MRT-2359 previously received Fast Track Designation in patients with previously treated, metastatic NSCLC with L-MYC or N-MYC expression, Orphan Drug Designation in small cell lung cancer (SCLC), and Fast Track Designation in previously treated, metastatic SCLC with L-MYC or N-MYC expression.